Page 1

Media Information 2018

IBI is a Peer Reviewed Journal. Please refer to the

Editorial topics listed are subject to change, according

Editorial Guidelines section on the

to the movement of the industry. We will be pleased to

biopharmaceuticalmedia.com website for

hear from you if you have relevant topics you would like

Peer Review Protocol and Author Guidelines.

to contribute within the journal. Please email all your suggestions to:

info@ibijournal.com


MEDIA INFORMATION

Biopharmaceuticals

most

Only through a combination of strong science and

sophisticated and elegant achievements of modern

deep operational excellence will the biopharma

science. The huge, complex structures of these

industry be able to fulfill its potential to transform the

drugs don’t just look extraordinary in the 3-D

health expectations of millions of people across the

modeling systems used to design them; they also

globe, successfully navigating both the promising

perform their jobs remarkably well, offering high

and challenging elements of the sector.

are

among

the

efficacy and few side effects. And there is much more to come: existing treatment archetypes are

In order to achieve this objective, it is essential for

evolving and becoming more sophisticated all the

the executives of this dynamic industry to constantly

time and continuing research is yielding entirely new

keep themselves educated in the latest technology,

types of products. Radically new concepts are

market

making it to the market, which offer even more

guidelines to gain a competitive edge.

information,

regulatory

and

validatory

amazing promises of regenerative medicine or disease

remission.

in

Peer reviewed by our carefully selected editorial

biopharmaceuticals is big and growing too rapidly to

advisory panel, and extensive research network, IBI,

ignore. Today, biopharmaceuticals generate global

provides

revenues of $163 billion, making up about 20

communication to the biopharmaceutical industry,

percent of the pharma market. The efficacy and

the latest in research and technology innovations,

safety of biopharmaceutical products, combined with

regulatory guidelines, marketing and communication

their

untreatable

strategies which will enable them to be more

conditions, allows pharma companies to command

efficient, bring products to market faster, reduce cost

high prices for innovative drugs. Strong demand has

and make healthcare accessible to all.

ability

to

address

The

opportunity

previously

a

proven

supportive

means

of

driven significant profits, despite the high cost of goods sold. Biopharmaceuticals have set new standards for blockbuster drugs as well. companies must continually evolve both their technologies and

biopharmaceuticalmedia.com

their operational capabilities. Technologies are not yet sufficiently mature to rely only on operational improvement to drive quality and productivity up and cost down. Nor will technological improvements alone be sufficient to do those things.

CONTACT

INFO@IBIJOURNAL.COM

T + 44(0)207 2372036


MEDIA INFORMATION

CIRCULATION AND READERSHIP International Biopharmaceutical Industry is a globally distributed publication

GEOGRAPHICAL PROFILE

with a presence across the world. Each quarterly issue will have a print copy distribution figure of

Europe

22,300 copies, providing strong access to the

Americas

International Market. IBI is sent directly to key decision makers in the Life

Asia

Sciences Industry, addressing all stakeholders. ROW

9,535

7,442

2,836

2,487

INDUSTRY BREAKDOWN Pharma / Biotech

37%

Drug Discovery/ Academia

12%

Bio Manufacturing / Development

11%

Analytical & Biochemical Laboratories

10%

Clinical Research Services

8%

Contract Services

7%

Finance / Legal Company

6%

Technology / Data Management Supplier

5%

Others including Industry Association, Drug Consultants, Regulatory Authorities & Governments

4%

DISTRIBUTION BY JOB FUNCTION Corporate Management Heads of Preclinical & Early Phase

12%

Regulatory Affairs

10%

Heads of Research & Development

10%

Heads of Clinical Research

8% 7%

Heads of Procurement Heads of Formulation Development

CONTACT

22%

6%

Heads of Business Development, Brand Managers, Sales & Marketing

5%

Medical Directors

5%

Heads of Production

5%

Logistics & Supply Chain Managers

5%

Heads of Medical Devices

5%

INFO@IBIJOURNAL.COM

T + 44(0)207 2372036


MEDIA INFORMATION

RATES AND DATA

International Biopharmaceutical Industry provides print advertisements and a package of digital marketing services, dedicated to assist you with your marketing campaigns.

Hard Copy Print Advertising Rates Double Page

£5,250

Full Page

£2,850

Half Page (Vertical / Horizontal)

£1,650

Prime Positions: Inside Front Cover

£5,950

Inside Back Cover

£4,850

Outside Back Cover

£7,250

Page Opposite Contents

£3,750

Page Opposite Editor’s Letter

£3,750

1 Page Corporate Profile

£2,000

Front Cover LOGO

£1,500

Book more than one insertion and the rates will be discounted. Inserts, reprints and recruitment advertisers’ rates are available on application. For more information contact: sales@ipimedia.com

Mechanical Data (In Millimetres, Height x Width, with Type, Trim, Bleed)

Type

Trim

Bleed

Full Page:

273 x 186

297 x 210

303 x 213

½ Pages:

135 x 186

148 x 210

151 x 213

273 x 92

297 x 105

303 x 108

(Horizontal)

½ Pages: (Vertical)

Please supply digitally, ideally a press ready PDF.

For Advertising Contact

Alternatively supply as a flat image file (Tiff, Jpeg, EPS,

Clive Baigent

PSD etc) ensuring that all fonts are embedded, images are

T: +44 (0) 01303 487583

High-resolution and the file is CMYK

Email: clive@ibijournal.com

CONTACT

INFO@IBIJOURNAL.COM

T + 44(0)207 2372036


MEDIA INFORMATION

DIGITAL COMPANY PROFILE

Lists your company, its contact details and key features of your company Publish more information about your company, product information, product pictures or site pictures, events you attend or job vacancies. Link them to various pages within your website.

First Page View

Company Profile View

Benefits Include: 

Company news will be published in the IBI eNewsletter and sent to more than 10,500 industry professionals.

Full usage stats are available

Rates: The price is £2,000 for a 12 month contract, equivalent to just £166 per month

CONTACT

INFO@IBIJOURNAL.COM

T + 44(0)207 2372036


MEDIA INFORMATION

DIGITAL ADVERTISING

Your banner will stay live for the length of the online booking and / or the duration of your print schedule. Mast Head Banner 728 x 90 px Rate: £900 per 3 months

Right Column Rectangle Banner (Or Company LOGO) 300 x 250 px Rate: £700 per 3 months Upload Your Video £800 for 3 months and thereafter £150 per month Right Column Rectangle 300 x 250 px Rate: £700 per 3 months Right Column Skyscraper 300 x 600 px Rate: £800 per 3 months

Other Positions Sponsored Articles: Rate: £400 per 3 months Events Listing Rate: £150 per months

Left Column Skyscraper

Popup Banner

300 x 600 px

640 x 480 px

Rate: £800 per 3 months

Rate: £1,800 per 3 months

CONTACT

INFO@IBIJOURNAL.COM

T + 44(0)207 2372036


MEDIA INFORMATION

SOCIAL MEDIA

International Biopharmaceutical Industry is active on the following social media channels. By adding Social Media for marketing purposes can increase your website traffic, gain attention to your brand and reach your target audience through social channels. Your customers are following and interacting with brands through social media, so having a strong online strategy and presence across social media is essential.

IBI is now active on twitter. Follow us on: https://twitter.com/biopharmaceuticalmedia

IBI is now active on Facebook. Follow us on: https://www.facebook.com/biopharmaceuticalmedia/

IBI is now active on Google +. Follow us on: https://plus.google.com/+Biopharmaceuticalmagazine

IBI is now active on Tumblr. Follow us on: http://biopharmaceuticalmedia.tumblr.com/

As part of your marketing and advertising campaign we will now provide you with access to our industry targeted social media channels. Send us your press release, product news or whatever is rocking in the industry, and it will be broadcasted through our social media sites.

CONTACT

INFO@IBIJOURNAL.COM

T + 44(0)207 2372036


MEDIA INFORMATION

IBI EDITORIAL CALENDAR 2018

IBI – International Biopharmaceutical Industry is peer reviewed. Supported by a team of industry experts, IBI brings you contemporary and authoritative articles which will guide the industry in the best practice in regulatory issues, market analysis, drug discovery, development, delivery methods, clinical research, laboratories, analytical testing, custom and contract manufacturing, logistics and supply chain management and finance and investment. Please visit our website: www.biopharmaceuticalmedia.com, to view our Peer Review Protocol, and Author Guidelines.

EDITORIAL TOPICS INCLUDE

CONTACT

Business & Outsourcing

Discovery Technology

Bioprocessing & Manufacturing

Research & Innovation

Biomarker Development

Technology Transfer Modelling & Simulation

Lab Equipment

Bio Imaging

Logistics & Supply Chain

Information Technology

Antibody Development & Protein Cells

Fermentation, Cell Culture & Expression

INFO@IBIJOURNAL.COM

T + 44(0)207 2372036


MEDIA INFORMATION

EDITORIAL CONTENT FOCUS IBI

Watch Pages

International Biopharmaceutical Industry Journal,

Short bite sized regular information on Enforcement,

provides

operating procedures, working with FDA, EMA, and

the

biopharmaceutical

comprehensive

coverage

of

industry key

with

scientific,

other compliance issues written by experts.

technology, regulatory and business topics.

Technical Articles: The editorial mix of peer-reviewed papers, practical

Feature articles in IBI offers timely technical and

advice on managing bioprocessing and technology,

scientific discussions of ongoing drug development

regulatory and business columns, and expert

challenges and solutions. Topics cover the full

commentary provides comprehensive coverage of

spectrum of biopharmaceutical development and

upstream

manufacturing

and

downstream

processing,

including

upstream

processing,

manufacturing operations, regulations, formulation,

downstream processing, manufacturing, quality and

scale-up/technology

regulations, analytics, facilities and equipment,

transfer,

drug

delivery,

laboratory operations, packaging, logistics, supply

analytical testing and more.

chain and business issues including intellectual The insight and analysis covers biologic – based therapies

including

biosimilars/biobetters, vaccines,

cell/gene

monoclonal protein therapies,

property, market research and funding.

antibodies, therapeutics,

antibody

drug

Regulatory Section: The latest developments, guidance documents &

conjugates and other emerging therapies.

enforcement action from international regulatory

We will report on emerging trends, strategies and

authorities

best practices in the key areas.

addressed.

IBI Publishes:

Outsourcing:

as

well

as

expert

analysis,

are

Peer Reviewed papers in the form of technical

Contract Service providers and users stay current

case studies, application notes; topical literature or

on trends, partnerships and business activities

patent reviews; novel research; or science based

through this section.

opinion papers. All papers undergo a peer review process by IBI’s Editorial Advisory Board of

New Products:

scientists, managers, directors and consultants.

New products for bioprocessing applications and analytical testing are profiled in each issue.

For Author Guidelines & Peer Review Protocol please visit our website at www.biopharmaceuticalmedia.com CONTACT

INFO@IBIJOURNAL.COM

T + 44(0)207 2372036


EDITORIAL CALENDAR 2018

Volume 1 Issue 1 [Publishing Month - April 2018]

Editorial Submission Deadline - 9th Mar 2018

Research / Innovation / Development Watch Pages Biologics

Early Development Pipeline  Biologic-Drug

Recombinant therapeutics Immunotherapy

Formulation

Antibody drug conjugates Gene and cell therapies Biologics, a game-changer in treatments delivered by self-injection Biotech ways of improving the productivity of drug development: rational drug design, combinatorial chemistry, in silico experimentation Analytical technology for biopharmaceuticals The rising tide of functional data from study of the human and other genomes, aiding in drug discovery

Upstream Processing 

Cell Culture

Downstream Processing 

Cell Harvesting

Manufacturing

High throughput proteomics work stations for applications such as MALDI TOF MS target

spotting and protein crystallization

Protein Therapeutics Development

Clinical Research

Quality/Regulations  Process Validation

Optimizing the design of clinical trials Toxicology studies, molecular biomarkers, imaging and companion diagnostics Oncolytic Viruses

Analytics  Advances in Analytics Operations  Facilities

Regulatory / Quality Compliance Navigating the shifting global and national regulatory landscape Fighting counterfeiting/ serialization

Manufacturing / Technology platforms

Packaging  Clinical Trials Materials Outsourcing  Outsourcing Manufacturing

The patient-first business model - Adapting to patient-centred models through advancements in technology The challenge of digitalization for drug manufacturers The rise of the analytics

Bio Business 

Partnering

Managing data in the New Health Economy

Supply Chain & Operations Managing global supply chains Predicting security and supply risks Building flexible supply chains Supply chain visibility Optimization and cost management

For Information on Conferences & Exhibitions attended by IBI please visit the website at - www.biopharmaceuticalmedia.com

CONTACT

INFO@IBIJOURNAL.COM

+44 (0) 207 2372036


EDITORIAL CALENDAR 2018

Volume 1 Issue 2 [Publishing Month - July 2018]

Editorial Submission Deadline – 9th Jun 2018

Research / Innovation / Development High-throughput screening (HTS) solutions The increasing use of protein arrays and DNA microarrays

Watch Pages Early Development Pipeline  Protein Therapeutics

The rising number of potential drug targets for screening

Upstream Processing  Bioreactors

Chemical synthesis and biological testing The potential of biosimilars Current methods of rational drug design High throughput screening, databases and proprietary algorithms Products for virtual screening and database building Emerging Trends in Healthcare and Drug Development Optimizing bioavailability using particle engineering, improving drug safety and ADME,

Downstream Processing  Cell Harvesting Manufacturing  Biosimilars

and genomics Work stations, automating assays, and sample preparation.

Clinical Research

Quality/Regulations  International Regulations Analytics

Providing better safety profiles of trial compounds Cell & Gene Therapy

Microbial Contamination

Operations

Clinical Monitoring Stem cell therapies

Regulatory / Quality Compliance

Equipments

Lab Operations

Supply Chain Pricing and reimbursement

Cool Chain

Boosting the drug pipelines through acquisitions, licensing deals and research

Outsourcing

collaborations The harmonisation of regulations & policies [keeping up with the rising demands of

Outsourcing Manufacturing

regulators (FDA)]

Manufacturing / Technology platforms

Bio Business 

Intellectual Property

Electronic medical records High resolution medical imaging New methods for rapid acquisition of data sets in cloud-based storage Developing innovative manufacturing pathways for APIs

Supply Chain & Operations GDP requirements: the understanding and application of Quality Risk Management (QRM) The control of outsourced transportation activities The challenges of applying QRM The importance of identifying and supporting acceptable levels of risk in regards to temperature excursions and proactive oversight For Information on Conferences & Exhibitions attended by IBI please visit the website at - www.biopharmaceuticalmedia.com

CONTACT

INFO@IBIJOURNAL.COM

+44 (0) 207 2372036


EDITORIAL CALENDAR 2018

Volume 1 Issue 3 [Publishing Month - October 2018]

Editorial Submission Deadline – 9th Sept 2018

Research / Innovation / Development Challenges in the development of small-molecule drugs Automation of biological assays

Watch Pages Early Development Pipeline 

Monoclonal Antibodies

API development Challenges for formulation and delivery of nanotech drugs Solutions for optimized delivery The cGMP standards for clinical research – how to meet the requirements for identity, strength, quality and purity in API manufacturing The healthcare digitization trends Biomarker identification for targeted therapies Biologics

Upstream Processing 

Cell Culture

Downstream Processing 

Separation & Purification

Manufacturing 

Fluid Handling Systems

The penetration of biologic drugs: monoclonal antibodies, recombinant proteins,

Quality/Regulations

peptides, cell and gene therapy products

Clinical Research

API Development and Approval Trends

Using CROs to optimize patient recruitment in clinical trials Early stage trials / Viral vectors

Analytics  Extractables & Leachables Testing

Vaccines

Regulatory / Quality Compliance

Operations 

Recent developments in cellular immunotherapy: IP and patents

Process Monitoring/Controls

The business case for the identification of medicinal products (IDMP) implementation Regulation of biotech products in the global pharma market

Packaging  Aseptic Manufacturing Processes

Manufacturing / Technology platforms The approach of continuous manufacturing Manufacturing cost containment and expansion Antibody library construction and screening, genomic testing, and cell-line development Optimal trial design strategies for phase I and proof of principle/concept.

Outsourcing 

Outsourcing Analytics

Bio Business  

Economic Development Investment Outlook

Supply Chain & Operations Achieving supply chain flexibility: 3PL partnerships IoT solutions Supply chain innovations The sustainability issue: Leaner and Greener The impact of digitalization

For Information on Conferences & Exhibitions attended by IBI please visit the website at - www.biopharmaceuticalmedia.com

CONTACT

INFO@IBIJOURNAL.COM

+44 (0) 207 2372036


EDITORIAL CALENDAR 2018

Volume 1 Issue 4 [Publishing Month - December 2018]

Editorial Submission deadline – 9th Nov 2018

Research / Innovation / Development Biomarkers, molecular imaging, companion diagnostics Innovative solutions for immuno-oncology drug discovery Target Identification/Target Validation Novel therapeutics addressing the unmet needs New technologies for reducing the cost and lead time of drug development Building capabilities to differentiate in the area of Target Identification/Target Validation Novel therapeutics addressing the unmet needs Use of next-generation sequencing in-vitro diagnostics Opportunities for biologics delivery Advancements in drug discovery technologies: such as iPS cells, automated high content

Watch Pages Early Development Pipeline 

Biosimilars/Biobetters

Upstream Processing 

Expression Systems

Downstream Processing 

Residual Impurities

Manufacturing 

Fill Finish

screening, patch clamp, gene editing and DNAencoded libraries

Quality/Regulations

Clinical Research The development of cell lines, contract manufacturing of developmental biologic drugs to support clinical development at various stages, and bio-analysis and product characterization Oncology Immunology

Process validation

Lot Release Testing

Analytics  Endotoxin Testing Operations 

Regulatory / Quality Compliance Safety and regulatory solutions for biopharmaceutical companies Considerations for Outsourcing the clinical, safety and regulatory activities The politics of global regulation

Lab Operations

Supply Chain 

Logistics/Shipping

Outsourcing

Manufacturing / Technology platforms New models of collaborative research

Outsourcing Development

Bio Business

Proteomics in anticancer drug discovery

Partnering

Human protein microarray for various protein analysis Avoiding hidden costs in conducting clinical trials

Supply Chain & Operations The Big Data Revolution Integration of medical apps Integrating Serialization and Track and Trace Systems into the Supply Chain Data delivery: how to collect, analyze and package data for success

For Information on Conferences & Exhibitions attended by IBI please visit the website at - www.biopharmaceuticalmedia.com

CONTACT

INFO@IBIJOURNAL.COM

+44 (0) 207 2372036


Contacts:

International Biopharmaceutical Industry Tower Bridge Business Complex 100 Clements Road London – SE1 5RT T:

+44 (0) 207 2372036

E:

info@ibijournal.com

W:

www.biopharmaceuticalmedia.com

Advertising: C. Baigent clive@ibijournal.com Editorial O. Breenan orla@ibijournal.com Production V. Toteva virginia@ibijournal.com Subscriptions M. Wright martin@ibijournal.com

Ibi media information 2018  
Ibi media information 2018  
Advertisement